Sai Parenterals targets ₹750 crore revenue as it pivots to monetization
Management expects FY27 revenue of ₹750 crore and 17% EBITDA margins as the company shifts from an investment phase to asset monetization.
What's new
- Management targets ₹750 crore revenue and 17% EBITDA margins for FY27.
- The Adelaide facility in Australia is scheduled for commissioning by March 2027.
- Backward integration of Nu-Med starts in Q4, aiming for a 2.4% margin lift.
Why this matters
The company is entering a transition period where it must balance a ₹440 crore capex plan with rising debt. Management claims FY27 marks the peak for net debt at ₹319 crore, making the successful commissioning of the Adelaide plant the primary test for future deleveraging.
What we're watching
- Actual margin changes following the Nu-Med integration in Q4.
- Progress on the ₹440 crore capex timeline for the Adelaide facility.
- Debt reduction trends starting in FY28 as promised.
The full read
Sai Parenterals is moving from an investment phase into asset monetization, setting a revenue target of ₹750 crore for FY27. Management expects EBITDA margins to hit 17%, aided by the backward integration of its Australian subsidiary, Nu-Med, which begins in the fourth quarter and is expected to contribute a 2.4 percentage point margin lift. The company is currently executing a ₹440 crore capex program, with the Adelaide facility in Australia scheduled for commissioning by March 2027. While the company expects net debt to peak at ₹319 crore in FY27, management claims this will be the high-water mark, with debt levels falling from FY28. The shift from heavy spending to asset returns is the central narrative for the year ahead.
Questions answered
- What is the company's revenue and margin guidance for FY27?
- Sai Parenterals targets revenue of ₹750 crore and an EBITDA margin of 17% for the current fiscal year.
- How does the company plan to improve its margins?
- Management plans to begin backward integration of its Australian subsidiary, Nu-Med, in the fourth quarter, which it expects will lift margins by 2.4 percentage points.
- What is the status of the company's capital expenditure?
- The company has a ₹440 crore capex program underway, with the Adelaide facility in Australia scheduled for commissioning by March 2027.
- What is the outlook for the company's debt levels?
- Management expects FY27 to be the peak year for debt, with net debt reaching ₹319 crore, before declining from FY28 onwards.